Swedish Orphan Biovitrum Management
Management criteria checks 3/4
We currently do not have sufficient information about the CEO.
Key information
Guido Oelkers
Chief executive officer
kr48.9m
Total compensation
CEO salary percentage | 25.1% |
CEO tenure | 7yrs |
CEO ownership | 0.1% |
Management average tenure | 5.3yrs |
Board average tenure | 3.5yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
Date | Total Compensation | Salary | Company Earnings |
---|---|---|---|
Mar 31 2024 | n/a | n/a | kr2b |
Dec 31 2023 | kr49m | kr12m | kr2b |
Sep 30 2023 | n/a | n/a | kr3b |
Jun 30 2023 | n/a | n/a | kr3b |
Mar 31 2023 | n/a | n/a | kr3b |
Dec 31 2022 | kr47m | kr11m | kr3b |
Sep 30 2022 | n/a | n/a | kr2b |
Jun 30 2022 | n/a | n/a | kr3b |
Mar 31 2022 | n/a | n/a | kr3b |
Dec 31 2021 | kr42m | kr10m | kr3b |
Sep 30 2021 | n/a | n/a | kr3b |
Jun 30 2021 | n/a | n/a | kr3b |
Mar 31 2021 | n/a | n/a | kr3b |
Dec 31 2020 | kr33m | kr10m | kr3b |
Sep 30 2020 | n/a | n/a | kr3b |
Jun 30 2020 | n/a | n/a | kr3b |
Mar 31 2020 | n/a | n/a | kr4b |
Dec 31 2019 | kr33m | kr10m | kr3b |
Sep 30 2019 | n/a | n/a | kr3b |
Jun 30 2019 | n/a | n/a | kr3b |
Mar 31 2019 | n/a | n/a | kr3b |
Dec 31 2018 | kr26m | kr9m | kr2b |
Sep 30 2018 | n/a | n/a | kr2b |
Jun 30 2018 | n/a | n/a | kr2b |
Mar 31 2018 | n/a | n/a | kr1b |
Dec 31 2017 | kr16m | kr5m | kr1b |
Compensation vs Market: Guido's total compensation ($USD4.52M) is above average for companies of similar size in the German market ($USD3.29M).
Compensation vs Earnings: Guido's compensation has been consistent with company performance over the past year.
CEO
Guido Oelkers (58 yo)
7yrs
Tenure
kr48,883,000
Compensation
Dr. Guido Oelkers is a Director of Dova Pharmaceuticals Inc. since November 12, 2019. Dr. Oelkers has been the Chief Executive Officer and President at Swedish Orphan Biovitrum AB since May 22, 2017. He se...
Leadership Team
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
CEO & President | 7yrs | kr48.88m | 0.11% SEK 9.0m | |
Chief Financial Officer | 5.8yrs | no data | 0.015% SEK 1.2m | |
General Counsel & Head of Legal Affairs | 5.3yrs | no data | 0.0079% SEK 642.4k | |
Head of Strategy & Corporate Development | 2.3yrs | no data | 0.0058% SEK 472.4k | |
Head of Human Resources | 1.3yrs | no data | no data | |
Senior Scientific & Medical Advisor | 7.3yrs | no data | 0.0047% SEK 384.1k | |
Head of International | 6.6yrs | no data | 0.010% SEK 836.1k | |
Head of Europe | 5.3yrs | no data | 0.0078% SEK 638.3k | |
Head of North America | 3.3yrs | no data | no data | |
Head of Strategic Transformation Operations | no data | no data | 0.0018% SEK 150.4k | |
Head of Technical Operations | 2.2yrs | no data | 0.0030% SEK 248.5k | |
Senior VP | 1.3yrs | no data | no data |
5.3yrs
Average Tenure
55.5yo
Average Age
Experienced Management: B6E's management team is seasoned and experienced (5.3 years average tenure).
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Chairman of Scientific Advisory Board | 23.3yrs | kr158.00k | no data | |
Director | 13.1yrs | kr828.00k | 0.0059% SEK 480.6k | |
Director | less than a year | kr463.00k | 0.00088% SEK 71.9k | |
Member of Scientific Advisory Board | no data | no data | no data | |
Member of Scientific Advisory Board | no data | no data | no data | |
Member of Scientific Advisory Board | no data | no data | no data | |
Member of Scientific Advisory Board | no data | no data | no data | |
Independent Chairman | 10yrs | kr770.00k | 0.0010% SEK 81.7k | |
Independent Director | 4yrs | kr827.00k | 0.0019% SEK 156.1k | |
Director | 3yrs | kr673.00k | 0.00015% SEK 12.3k | |
Employee Representative Director | 1.3yrs | no data | no data | |
Independent Director | less than a year | kr433.00k | no data |
3.5yrs
Average Tenure
53.5yo
Average Age
Experienced Board: B6E's board of directors are considered experienced (3.5 years average tenure).